Literature DB >> 18513255

Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.

Susanne M Picker1, Alexander Steisel, Birgit S Gathof.   

Abstract

BACKGROUND: The aim of this study was to examine the effects of a new riboflavin-based pathogen reduction technology (PRT), the Mirasol PRT process (Navigant Biotechnologies) on platelet (PLT) storage lesion development. STUDY DESIGN AND METHODS: A three-arm in vitro study was conducted comparing cell quality of apheresis PLTs (n = 12 each) treated with Mirasol PRT (M) to untreated (C) and gamma-irradiated units (X) collected from the same donors and stored for up to 7 days under equal conditions.
RESULTS: PLT count, lactate dehydrogenase, and K+ release of M units were not significantly different from C units, indicating retention of cell integrity during storage. The immediate effect (Day 1) of PRT treatment was a significant decrease in hypotonic shock response (M, 80.6 +/- 7.8% vs. 89.2 +/- 8.3%) and aggregation (M, 85.7 +/- 15.2%/min vs. 111.8 +/- 31.5%/min) as well as a significant acceleration of mitochondrial membrane depolarization (M, 1.43 +/- 0.44% vs. 0.91 +/- 0.27%) and P-selectin expression (M, 38.4 +/- 13.8% vs. 15.8 +/- 7.7%) resulting in lower swirl scores on Day 5 (1.5 +/- 0.7 vs. 2.7 +/- 0.4). Significantly higher glucose consumption (60 +/- 13 nmol/10(12) cells/hr vs. 31 +/- 9 nmol/10(12) cells/hr) and lactate production rates (82 +/- 17 nmol/10(12) cells/hr vs. 40 +/- 8 nmol/10(12) cells/hr) caused higher acidity in treated units (pH on Day 5, 6.97 +/- 0.15 vs. 7.42 +/- 0.10). After PRT treatment, oxidative metabolism was still active and, from calculation of oxygen consumption (1.09 +/- 0.23 nmol/min/10(9) PLTs), appeared to be up regulated relative to controls (0.76 +/- 0.27 nmol/min/10(9) PLTs).
CONCLUSION: Although storage variables clearly showed the effects of PRT treatment, apheresis PLTs treated with Mirasol PRT retained cell quality during 5 days of storage without loss of mitochondria-based oxidative respiration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18513255     DOI: 10.1111/j.1537-2995.2008.01778.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

Review 1.  Emerging Pathogens - How Safe is Blood?

Authors:  Michael Schmidt; Wolf-Jochen Geilenkeuser; Walid Sireis; Erhard Seifried; Kai Hourfar
Journal:  Transfus Med Hemother       Date:  2013-12-27       Impact factor: 3.747

2.  The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

Authors:  Håkon Reikvam; Susanne Marschner; Torunn Oveland Apelseth; Ray Goodrich; Tor Hervig
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

3.  Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction.

Authors:  Susanne M Picker; Larissa Oustianskaia; Volker Schneider; Birgit S Gathof
Journal:  Transfus Med Hemother       Date:  2010-01-07       Impact factor: 3.747

4.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

5.  Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation.

Authors:  Lacey Johnson; Denese Marks
Journal:  Transfus Med Hemother       Date:  2015-05-07       Impact factor: 3.747

6.  Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA).

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11-18       Impact factor: 3.117

7.  Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.

Authors:  Anno Saris; Ivan Peyron; Pieter F van der Meer; Tor B Stuge; Jaap Jan Zwaginga; S Marieke van Ham; Anja Ten Brinke
Journal:  Front Immunol       Date:  2018-06-05       Impact factor: 7.561

Review 8.  Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.

Authors:  Gines Escolar; Maribel Diaz-Ricart; Jeffrey McCullough
Journal:  Transfusion       Date:  2021-12-06       Impact factor: 3.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.